Prodrugs of Analogs of Nucleic Acid Components

Abstract

This review regards various attitudes to the rational design of prodrugs derived of nucleoside and nucleotide analogues with pronounced biological (antiviral, anticancer) activity. Particular attention is focused on the recent development of prodrugs of approved therapeutic agents with the above structural association.